In NSCLC patients with BRAF V600E mutation, the objective response rate (ORR) of dabrafenib combined with trametinib exceeds 60%, regardless of prior treatment status (treatment-naive or resistant to first-line chemotherapy). This evidence concerns the gene BRAF and non-small cell lung carcinoma.